Airsculpt Technologies (AIRS) risk factors, FY2024 10-K

Risks Related to Our Business

1. 01Our operating results could be adversely affected if we are unable to successfully implement certain cost savings initiatives and revenue growth strategies
2. 02Macroeconomic trends including inflation and rising interest rates may adversely affect our financial condition and results of operations
3. 03We have a limited operating history and our past results may not be indicative of our future performance. Further, our revenue growth rate is likely to slow as our business and our market matures
4. 04Our success depends on our ability to maintain the value and reputation of the AirSculpt® brand
5. 05We have grown rapidly in recent years and have limited operating experience at our current scale of operations. If we are unable to manage and capitalize on our scale effectively, our brand, company culture, and financial performance may suffer
6. 06We are dependent upon the success of the AirSculpt® body sculpting procedure. If market acceptance for the AirSculpt® procedure fails to grow significantly, our business and future prospects could be harmed
7. 07If there is not sufficient patient demand for AirSculpt® procedures, our financial results and future prospects will be harmed
8. 08Our success depends largely upon patient satisfaction with the effectiveness of the AirSculpt® procedure
9. 09Our long-term growth strategy depends, in large part, on growing and operating our new centers, including five opened in 2024, both in existing and new geographic regions, particularly in densely populated and affluent metropolitan and suburban regions
10. 10Our failure to effectively address challenges such as these could adversely affect our ability to successfully operate new centers in a cost-effective manner
11. 11If we cannot maintain our high-performance and client-focused culture as we grow, we could lose the innovation and passion that we believe contribute to our success and our business may be harmed
12. 12To successfully continue to grow in markets outside of North America, we must address many issues with which we have limited experience
13. 13If one or more of these risks were realized, it could require us to dedicate significant financial and management resources and our revenue may decline
14. 14continue to dedicate, significant resources to aggressively develop and commercialize their products. For example, in 2023, certain drugs initially approved for use in diabetes patients gained market acceptance for use in weight loss treatment following FDA approvals for weight loss indications
15. 15Our business, financial condition and results of operations could be adversely affected by disruptions in the global economy resulting from the ongoing military conflict between Russia and Ukraine
16. 16Use of social media may materially and adversely affect our reputation or subject us to fines or other penalties
17. 17Our business relies heavily on email and other messaging services, and any restrictions on the sending of emails or messages or an inability to timely deliver such communications could materially adversely affect our net revenue and business
18. 18Changes in laws and regulations related to the internet, perceptions toward the use of social media and changes in internet infrastructure itself may diminish our ability to drive new customer acquisition and could adversely affect our business and results of operations
19. 19Regulations related to healthcare, including telehealth, are evolving. To the extent regulations change, our ability to provide virtual consultations could be hampered
20. 20The number of surgeons available to work through our affiliated Professional Associations at our centers is finite, and we face intense competition from other cosmetic treatment centers in recruiting surgeons to work in our centers
21. 21We rely on a skilled, licensed labor force to provide our medspa and cosmetic services, and the supply of this labor force is finite. If we cannot hire adequate staff for our clinics, we will not be able to operate
22. 22Our personnel or others may engage in misconduct or other improper activities, including noncompliance with our policies and procedures
23. 23We outsource the manufacturing of key elements of the tools we use for AirSculpt® procedures to a single third-party manufacturer
24. 24The manufacturing operations of Euromi are themselves dependent upon third-party suppliers, making us vulnerable to supply shortages and price fluctuations, which could harm our business
25. 25Some jurisdictions preclude us from entering into non-compete agreements with our surgeons, and other non-compete agreements and restrictive covenants applicable to certain surgeons and other employees may not be enforceable
26. 26We may become involved in litigation which could negatively impact the value of our business
27. 27Our centers and our affiliated Professional Associations providing professional services at such centers may become subject to medical liability and other legal claims, which could have a material adverse impact on our business
28. 28The health of the economy may affect consumer purchases of discretionary services, such as cosmetic services, which could have a material adverse effect on our business, financial condition and results of operations
29. 29Our revenue could decline due to changes in credit markets and decisions made by credit providers
30. 30Our centers are sensitive to regulatory, economic and other conditions in the states and jurisdictions where they are located
31. 31We depend on our senior management, and we may be adversely affected if we lose any member of our senior management
32. 32We rely on Vesey Street Capital Partners, L.L.C., our private equity sponsor and the interests of our Sponsor may conflict with the interests of the Company and its other stockholders
33. 33Our ability to pay or to refinance our indebtedness will depend upon our future operating performance, which will be affected by general economic, financial, competitive, legislative, regulatory, business and other factors beyond our control
34. 34Restrictive covenants in our debt instruments may adversely affect us
35. 35Despite our current indebtedness levels, we and our subsidiaries may still be able to incur more debt, which could further exacerbate the risks associated with our substantial leverage
36. 36Our ability to pay interest on and principal of our debt obligations principally depends upon our operating performance. As a result, prevailing economic conditions and financial, business and other factors, many of which are beyond our control, will affect our ability to make these payments
37. 37We are a holding company with no operations of our own
38. 38Our variable rate debt exposes us to risks associated with rising interest rates, which could adversely affect our cash flows
39. 39We may be subject to income and other taxes in the United States and foreign jurisdictions, and our domestic tax liabilities are subject to the allocation of expenses in differing jurisdictions
40. 40If there is a change in accounting standards by the Financial Accounting Standards Board or the interpretation thereof affecting consolidation of entities, it could have a material adverse effect on our consolidation of total revenue derived from the Professional Associations
41. 41Our management team has limited experience managing a public company
42. 42A pandemic, epidemic or outbreak of a contagious disease in the markets in which we operate or that otherwise impacts our centers could adversely impact our business
43. 43Our centers may be adversely impacted by weather and other factors beyond our control, and disruptions in our disaster recovery systems or management continuity planning could limit our ability to operate our business effectively
44. 44Use and storage of paper medical records increases risk of loss, destruction and could increase human error with respect to documentation and patient care
45. 45Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or our patients, or prevent us from accessing critical information or systems and expose us to liability, and could adversely affect our business and our reputation

Risks Related to Intellectual Property

1. 46If we are unable to obtain and maintain patent protection of sufficient scope or at all or freedom to operate for the AirSculpt® procedure or any technology we develop, our ability to successfully commercialize any procedures we may develop may be adversely affected
2. 47We seek to protect our position by filing patent applications in the United States and internationally related to our proprietary procedures and any products that we may develop that are important to our business
3. 48make the inventions claimed in our patents or pending patent applications or that we were the first to file for patent protection of such inventions
4. 49We may become a party to intellectual property litigation or administrative proceedings or other intellectual property challenges that could be costly and could interfere with our ability to market and perform our services
5. 50ours is invalid or unenforceable, in whole or in part, construe the patent’s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question
6. 51If we are unable to protect our other proprietary rights, our business and competitive position may be harmed
7. 52procedures and harm our business, the value of our investment in development could be reduced and third parties may make claims against us related to losses of their confidential or proprietary information
8. 53We may not be able to protect our intellectual property rights throughout the world to the same extent as in the United States
9. 54If our trademarks and trade names are not adequately protected, that could adversely impact our ability to build name recognition in certain markets

Risks Related to Government Regulations

1. 55If we fail to comply with or otherwise incur liabilities under the numerous federal and state laws and regulations relating to the operation of our centers, we could incur significant penalties or other costs or be required to make significant changes to our operations
2. 56If we fail or have failed to comply with applicable laws and regulations, we could subject ourselves to administrative, civil or criminal penalties, cease and desist orders, and loss of licenses necessary to operate
3. 57We cannot be certain if and when international regulatory agencies will approve use of the AirSculpt® procedure in their respective jurisdictions
4. 58AirSculpt® procedures may cause or contribute to adverse medical events that we are required to report to the FDA and if we fail to do so, we could be subject to sanctions that would materially harm our business
5. 59If laws governing the corporate practice of medicine or fee-splitting change, we may be required to restructure some of our relationships, which may result in a significant loss of revenue and divert other resources
6. 60We may be subject to various federal and state laws pertaining to healthcare fraud and abuse, including anti-kickback, self-referral, false claims and fraud laws, and any violations by us of such laws could result in fines or other penalties
7. 61We are subject to numerous environmental, health and safety laws and regulations, and must maintain licenses or permits, and non-compliance with these laws, regulations, licenses, or permits may expose us to significant costs or liabilities
8. 62Certain risks are inherent in providing prescription and over the counter (“OTC”) treatments, and our insurance may not be adequate to cover any claims against us
9. 63If antitrust enforcement authorities conclude that our market share in any particular market is too concentrated or that we violate antitrust laws, we could be subject to enforcement actions that could have a material adverse effect on our business, prospects, results of operations and financial condition
10. 64The healthcare laws and regulation to which we are subject is constantly evolving and may change significantly in the future

Risks Related to Ownership of Our Common Stock

1. 65We are an “emerging growth company,” as defined in the Securities Act, and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors
2. 66We filed a registration statement on Form S-3 with the SEC, and the number of shares of common stock being registered for sale is significant in relation to the number of our outstanding shares of common stock
3. 67Although we do not expect to rely on the “controlled company” exemption, we are a “controlled company” within the meaning of the Nasdaq listing standards, and we qualify for exemptions from certain corporate governance requirements
4. 68Our stock price could be extremely volatile, and, as a result, you may not be able to resell your shares at or above the price you paid for them
5. 69There may be sales of a substantial amount of our common stock by our current stockholders, and these sales could cause the price of our common stock to fall
6. 70Sales of substantial amounts of our common stock in the public market, or the perception that such sales will occur, could adversely affect the market price of our common stock and make it difficult for us to raise funds through securities offerings in the future
7. 71Future issuances of capital stock may dilute your percentage ownership in us, which could reduce your influence over matters on which stockholders vote
8. 72Certain of our directors and executive officers hold a substantial portion of our common stock, which may lead to conflicts of interest with other stockholders over corporate transactions and other corporate matters
9. 73Provisions in our charter documents and Delaware law may deter takeover efforts that could be beneficial to stockholder value
10. 74In addition, our board of directors has the right to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval that could be used to dilute the ownership of a potential hostile acquiror
11. 75Further, these choice of forum provisions may increase the costs for a stockholder to bring such a Proceeding and may discourage them from doing so
12. 76in our common stock unless you sell our common stock for a price greater than that which you paid for it
13. 77The requirements of being a public company may strain our resources and distract our management, which could make it difficult to manage our business, particularly after we are no longer an “emerging growth company” under the JOBS Act
14. 78Furthermore, if we are unable to satisfy our obligations as a public company, we could be subject to delisting of our common stock, fines, sanctions, and other regulatory action and potentially civil litigation, which could have a material adverse effect on our financial condition and results of operations
15. 79If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline
16. 80We may be subject to securities litigation, which is expensive and could divert management attention
17. 81Our quarterly operating results and other operating metrics may fluctuate from quarter to quarter, which makes these metrics difficult to predict
18. 82Any one of the factors above or the cumulative effect of some of the factors above may result in significant fluctuations in our operating results